Skip to content

Study · Observational study · n = 752 · 2024

5 results

Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).

Caballero Mateos I, García de Lucas MD, Doulatram-Gamgaram VK, Moreno-Moreno P, Jimenez-Millan AI, Botana-López M, Merino-Torres JF, Soto-Gónzalez A, Fernández-García JC, Morales-Portillo C

Nutrients3 Aug 2024Cited by 7 (Europe PMC)

PMID39125424 (opens in a new tab)PMCIDPMC11314012 (opens in a new tab)DOI10.3390/nu16152545 (opens in a new tab)PepBankPUB-39125424
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 diabetes mellitus (T2DM), these results need to be confirmed in a real-world (RW) setting. An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain. We evaluated changes in HbA1c and body weight in patients with T2DM treated with semaglutide OW s.c. Additionally, we analyzed different subgroups of patients treated with semaglutide OW s.c. as an add-on to glucose-lowering therapy. A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included. At 12 months, compared with baseline, there was a mean difference of -2.1% in HbA1c levels (p p < 0.001). Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy. Semaglutide OW s.c. was well tolerated, with gastrointestinal disorders being the most commonly reported side effects. In this RW study, 12 months of treatment with semaglutide OW s.c. in patients with T2DM was associated with significant and clinically relevant improvements in glycemic control and weight loss, regardless of the glucose-lowering therapy received, and the overall safety profile was positive.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in Spain, HbA1c at 12 months on once-weekly subcutaneous semaglutide was lower than at baseline, by a mean of 2.1%.

    In plain wordsIn adults with type 2 diabetes in Spain, HbA1c was lower after 12 months of weekly semaglutide than at the start.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change at 12 months
    Study

    n = 752

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    HbA1c mean difference
    −2.1%
    12 months versus baseline

    Source sentences

    Summary
    At 12 months, compared with baseline, there was a mean difference of -2.1% in HbA1c levels (p p < 0.001).
    2 context sentences
    Summary · context
    An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain.
    Summary · context
    A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in Spain, body weight at 12 months on once-weekly subcutaneous semaglutide was lower than at baseline, by a mean of 9.2 kg.

    In plain wordsIn adults with type 2 diabetes in Spain, body weight was lower after 12 months of weekly semaglutide than at the start.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 12 months
    Study

    n = 752

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Body weight mean difference
    −9.2 kg
    12 months versus baseline

    Source sentences

    Summary
    At 12 months, compared with baseline, there was a mean difference of -2.1% in HbA1c levels (p p < 0.001).
    3 context sentences
    Summary · context
    significant and clinically relevant improvements in glycemic control and weight loss
    Summary · context
    An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain.
    Summary · context
    A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included.
  3. 03HumanObservational studySafety outcome

    In adults with type 2 diabetes in Spain, once-weekly subcutaneous semaglutide was well tolerated, and gastrointestinal disorders were the most commonly reported side effects.

    In plain wordsIn adults with type 2 diabetes in Spain, weekly semaglutide was well tolerated; stomach and gut problems were the most common side effects.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedTolerability and gastrointestinal side effects
    Study

    n = 752

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Semaglutide OW s.c. was well tolerated, with gastrointestinal disorders being the most commonly reported side effects.
    2 context sentences
    Summary · context
    An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain.
    Summary · context
    A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included.
  4. 04HumanObservational studyEfficacy outcome

    In four subgroups of adults with type 2 diabetes receiving semaglutide as add-on to glucose-lowering therapy, HbA1c differed significantly between baseline and month 12.

    In plain wordsIn adults with type 2 diabetes who added semaglutide to other diabetes drugs, HbA1c changed significantly over 12 months in all four subgroups.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change in add-on subgroups
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy.
    2 context sentences
    Summary · context
    An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain.
    Summary · context
    A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included.
  5. 05HumanObservational studyEfficacy outcome

    In four subgroups of adults with type 2 diabetes receiving semaglutide as add-on to glucose-lowering therapy, body weight differed significantly between baseline and month 12.

    In plain wordsIn adults with type 2 diabetes who added semaglutide to other diabetes drugs, body weight changed significantly over 12 months in all four subgroups.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change in add-on subgroups
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy.
    2 context sentences
    Summary · context
    An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain.
    Summary · context
    A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.